CN101675072A - 胆固醇流出的有效和选择性的介质 - Google Patents

胆固醇流出的有效和选择性的介质 Download PDF

Info

Publication number
CN101675072A
CN101675072A CN200780046286A CN200780046286A CN101675072A CN 101675072 A CN101675072 A CN 101675072A CN 200780046286 A CN200780046286 A CN 200780046286A CN 200780046286 A CN200780046286 A CN 200780046286A CN 101675072 A CN101675072 A CN 101675072A
Authority
CN
China
Prior art keywords
polypeptide
amino acid
group
seq
constitutes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200780046286A
Other languages
English (en)
Chinese (zh)
Inventor
约翰·K·别利茨基
简·约翰松
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California, San Diego
Original Assignee
University of California, San Diego
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California, San Diego filed Critical University of California, San Diego
Publication of CN101675072A publication Critical patent/CN101675072A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN200780046286A 2006-12-13 2007-12-13 胆固醇流出的有效和选择性的介质 Pending CN101675072A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87490906P 2006-12-13 2006-12-13
US60/874,909 2006-12-13
PCT/US2007/087477 WO2008115303A2 (en) 2006-12-13 2007-12-13 Potent and selective mediators of cholesterol efflux

Publications (1)

Publication Number Publication Date
CN101675072A true CN101675072A (zh) 2010-03-17

Family

ID=39766652

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200780046286A Pending CN101675072A (zh) 2006-12-13 2007-12-13 胆固醇流出的有效和选择性的介质

Country Status (10)

Country Link
US (1) US8987192B2 (cg-RX-API-DMAC10.html)
EP (1) EP2121746B1 (cg-RX-API-DMAC10.html)
JP (1) JP2010513311A (cg-RX-API-DMAC10.html)
CN (1) CN101675072A (cg-RX-API-DMAC10.html)
AT (1) ATE533783T1 (cg-RX-API-DMAC10.html)
AU (1) AU2007349237B2 (cg-RX-API-DMAC10.html)
CA (1) CA2672131C (cg-RX-API-DMAC10.html)
DK (1) DK2121746T3 (cg-RX-API-DMAC10.html)
ES (1) ES2377329T3 (cg-RX-API-DMAC10.html)
WO (1) WO2008115303A2 (cg-RX-API-DMAC10.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105050614A (zh) * 2013-03-15 2015-11-11 加利福尼亚大学董事会 刺激胆固醇流出的具有降低的毒性的肽

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102123722A (zh) 2008-06-18 2011-07-13 加利福尼亚大学董事会 改进的胆固醇流出的肽介质
US20110152112A1 (en) * 2009-12-23 2011-06-23 Artery Therapeutics, Inc. Diagnosis and treatment of reverse cholesterol transport deficiency-related diseases
US20130123173A1 (en) * 2010-04-28 2013-05-16 The Regents Of The University Of California Creation of oxidation-resistant hdl mimetic peptides
WO2016044177A1 (en) * 2014-09-17 2016-03-24 The Regents Of The University Of California Peptides having reduced toxicity that stimulate cholesterol efflux
CN112442114A (zh) * 2019-08-29 2021-03-05 渥太华Hdl药物研发公司 一种多肽及其应用
CN112511569B (zh) * 2021-02-07 2021-05-11 杭州筋斗腾云科技有限公司 网络资源访问请求的处理方法、系统及计算机设备

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000055318A2 (en) 1999-03-15 2000-09-21 University Of British Columbia Abc1 polypeptide and methods and reagents for modulating cholesterol levels
ATE387459T1 (de) * 2000-04-06 2008-03-15 Kos Pharma Inc Verbindungen und methoden zur senkung des cholesterinspiegels ohne induktion von hypertriglyceridämie
US6664230B1 (en) * 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US7199102B2 (en) 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
EP1706131A4 (en) 2003-12-15 2009-08-12 Univ California THE CELLULAR CHOLESTEROL EFFLUX STIMULATING HELICULAR SYNTHETIC PEPTIDES
JP5048486B2 (ja) 2004-07-16 2012-10-17 トラスティーズ オブ タフツ カレッジ アポリポタンパク質a1の模倣物とその使用
US8541236B2 (en) 2006-12-08 2013-09-24 University Of Washington Mutant apolipoprotein A-1 polypeptide with increased resistance to oxidation and reactive carbonyls

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105050614A (zh) * 2013-03-15 2015-11-11 加利福尼亚大学董事会 刺激胆固醇流出的具有降低的毒性的肽
CN105050614B (zh) * 2013-03-15 2019-04-05 加利福尼亚大学董事会 刺激胆固醇流出的具有降低的毒性的肽

Also Published As

Publication number Publication date
WO2008115303A2 (en) 2008-09-25
CA2672131C (en) 2016-06-07
US8987192B2 (en) 2015-03-24
EP2121746B1 (en) 2011-11-16
ES2377329T3 (es) 2012-03-26
HK1138292A1 (en) 2010-08-20
WO2008115303A3 (en) 2008-12-24
AU2007349237A1 (en) 2008-09-25
ATE533783T1 (de) 2011-12-15
AU2007349237B2 (en) 2014-01-23
US20120329703A1 (en) 2012-12-27
CA2672131A1 (en) 2008-09-25
EP2121746A2 (en) 2009-11-25
DK2121746T3 (da) 2012-03-05
JP2010513311A (ja) 2010-04-30

Similar Documents

Publication Publication Date Title
AU2004299486B2 (en) Helical synthetic peptides that stimulate cellular cholesterol efflux
US8415293B2 (en) Peptide mediators of cholesterol efflux
AU2007221470B2 (en) Phosphatase inhibitor Protein-1 as a regulator of cardiac function
JP2003525565A (ja) アポリポタンパク質a−1アゴニストを供給するための遺伝子治療法および異常脂肪血障害を治療するためのその使用
EA024751B1 (ru) Мутанты fgf21 и их применение
US20210171586A1 (en) Peptides having reduced toxicity that stimulate cholesterol efflux
EP2121746B1 (en) Potent and selective mediators of cholesterol efflux
US6444644B1 (en) Anticoagulant peptide fragments derived from apolipoprotein B-100
Scott et al. Human apolipoprotein B: complete cDNA sequence and identification of structural domains of the protein
US20130123173A1 (en) Creation of oxidation-resistant hdl mimetic peptides
US20100204103A1 (en) Helical synthetic peptides that stimulate cellular cholesterol efflux
HK1138292B (en) Potent and selective mediators of cholesterol efflux
CN115666624A (zh) 作为抗癌治疗的emid2蛋白
Scanu 3/Plasma Apolipoproteins
HK1124614A (en) Compounds and methods for lowering cholesterol levels without inducing hypertriglyceridemia

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20100317